Similar Items: Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan
- Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan
- Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis
- Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy
- Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report
- Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis
- Repurposing Old Drugs: Roflumilast as a Promising Therapeutic Option for Plaque Psoriasis